entertainment -WSS

entertainment

author：leisure time 2025-10-01 17:21:44 - browse：9

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： STAT Summit: How researchers deal with rejection

Wikipedia

WSS

What the Wegovy shortage looks like for doctors — and for patients

STAT Summit: Meghan O’Rourke on making chronic illness visible

There’s no way to know how good AI health technologies are

STAT Summit: How researchers deal with rejection

Results on Novartis prostate cancer therapy could expand its use

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Wikipedia

entertainment

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How AI can help patients find reliable information about doctors

DIEP, the 'gold standard' of breast reconstruction, is under threat

European regulators consider appeal over Amylyx ALS drug

State Dept. review finds Biden bears some blame for Afghanistan failures

Better Therapeutics data on benefit with GLP

Medical records are filled with copy

How doctors and nurses shape Google's AI

New air purifier tech could be key to improving indoor air quality

Is there really a nursing shortage in the U.S.?

hotspot

STAT Summit: Ending the crisis of Black deaths in the U.S.

STAT Summit: How researchers deal with rejection

STAT Summit: The economic case for universal basic health care

Readout LOUD podcast: Merger Mondays, Ozempic panic

Questions loom on AstraZeneca cancer drug as safety concerns ebb

The problems with dementia villages

hotspot

Wikipedia

explore

hotspot